Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Becton Dickinson And Co's BD Rx Inc Announces FDA Approves Second Drug in BD Simplist Prefilled Injectable Line of Products


Tuesday, 23 Apr 2013 08:15am EDT 

BD Rx Inc., a wholly-owned subsidiary of Becton Dickinson And Co announced that the U.S. Food and Drug Administration (FDA) has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables. The second BD Simplist product to launch is Metoclopramide Injection, USP, an injectable antiemetic. BD Rx launched its first drug - BD Simplist Diphenhydramine Hydrochloride Injection, USP, an injectable antihistamine - on March 27, 2013. BD Simplist prefilled injectables are designed to help improve patient care and safety by decreasing the number of steps in the traditional vial and syringe injection sequence, reducing the potential risk of medication error. The potential for medication error exists with every injection. Clinicians perform up to 20 steps in a traditional vial and syringe injection sequence. But with BD Simplist prefilled injectables, the injection sequence is reduced to approximately 12 steps, reducing the potential risk of medication error and allowing for more focus on the patient and less on injection preparation. The Company plans to launch 20 to 30 drugs in its BD Simplist line of products during the next few years and is targeting generic injectables in doses commonly relied on by clinicians in both the hospital and surgical center settings. 

Company Quote

141.26
6.53 +4.85%
26 Nov 2014